Manal Abdelmalek

Professor of Medicine, Director MASLD Clinical Research

Mayo Clinic

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Manal Abdelmalek is a Professor of Medicine and the Director of MASLD Clinical Research at the Mayo Clinic in the United States. Her research focuses on metabolic dysfunction-associated steatohepatitis, hepatic fibrosis, and liver diseases related to diabetes and metabolic syndrome. She has authored several recent articles addressing topics such as the effects of weight loss on liver health, the protective role of statins, and emerging strategies for hepatocellular carcinoma prevention.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Sheng Luo

Duke University

UNITED STATES

View details

Diana Barb

Associate Professor

University of Florida

UNITED STATES

View details

David Kleiner

National Cancer Institute

UNITED STATES

View details

Matthew Loop

Assistant Professor

Auburn University

UNITED STATES

View details

Cynthia Moylan

Associate Professor

Duke University

UNITED STATES

View details

Bertrand Cariou

Université de Nantes

FRANCE

View details

Seema Khan

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Raluca Pais

Sorbonne Université

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Manal Abdelmalek

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Current and emerging strategies for the prevention of hepatocellular carcinoma

Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis

Age-specific protective effects of statins against cirrhosis in patients with chronic liver enzyme elevation associated with metabolic dysfunction: a retrospective cohort study of electronic health records

Betaine in the treatment of steatotic liver disease—Historical fad or a timeless treasure worth reviving?

Peppermint oil-associated hepatotoxicity

The Liver in Diabetes and Metabolic Syndrome

Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease

MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials

A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Steatotic liver disease, a useful construct in primary care that doesn’t upset the apple cart

A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

Reply: ELF in the risk stratification of NAFLD

Reply

Collaborators (8)

Sheng Luo

Diana Barb

David Kleiner

Matthew Loop

Cynthia Moylan

Bertrand Cariou

Seema Khan

Raluca Pais

Make your next move.